Herbalife Launches Bioniq GO in US, Expands Personalised Nutrition Following UK Acquisition
Herbalife has initiated its personalised micronutrient offering, Bioniq GO, in the US market, leveraging its recent £120.7 million acquisition of UK-based Bioniq. This move signifies Herbalife's strategic shift towards digital-led, tailored supplement solutions aimed at future growth.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Herbalife, a significant player in the nutrition sector, has commenced the US market rollout of Bioniq GO, a new personalised daily micronutrient supplement. This launch directly follows its Q1 2026 acquisition of UK-based personalised nutrition specialist, Bioniq, for $150 million (£120.7 million at current exchange rates). Bioniq GO employs a digital wellness assessment to tailor one of 40 micronutrient formulations, each comprising up to 23 vitamins and minerals, based on individual lifestyle and nutritional requirements. This initiative aligns with Herbalife's stated innovation strategy focused on making personalised nutrition scalable through science-backed products, digital technology, and existing distributor networks.
The Bioniq acquisition is part of a broader investment strategy by Herbalife into next-generation wellness solutions. Other recent investments include Link BioSciences, focusing on genomic and biological insights, and Pruvit, a ketone supplement company. Furthermore, Herbalife launched its Life I/O healthspan brand in late 2025, targeting cellular wellness and NAD+ levels. A notable prior acquisition, Pro2col, specialises in data-driven wellness plans, partially backed by footballer Cristiano Ronaldo, who also acts as a spokesperson.
Herbalife's shift towards personalised and digital health solutions is a calculated move to underpin future financial growth. The company reported robust Q2 2026 financial results, with net sales reaching $1.3 billion, a 5.4% year-over-year increase. Adjusted EBITA stood at $167 million, exceeding guidance when accounting for foreign currency fluctuations. In April 2026, Herbalife completed a $1.45 billion senior secured refinancing, expected to yield approximately $45 million in annual cash interest savings and improve financial flexibility. Despite a recent 'hold' rating downgrade from Wall Street Zen, MarketBeat projects Herbalife's earnings to grow 12.31% next year, from $2.68 to $3.01 per share.
What this means for United Kingdom
UK-based supplement manufacturers and brand owners should anticipate intensified competition in the personalised nutrition segment, driven by large-scale market entrants like Herbalife. The integration of Bioniq's UK expertise into Herbalife’s expansive network could redefine consumer expectations for bespoke supplement offerings. Manufacturers must evaluate their capacity for small-batch production and flexible ingredient sourcing to compete with tailored formulations. Regulatory teams should monitor MHRA guidance on digital assessment tools and personalised claims. This presents an opportunity for UK-based tech providers in health diagnostics to partner with established supplement brands seeking to emulate this hybrid digital-D2C model.
Herbalife CEO Stephan Gratziani stated the Bioniq launch in Europe and the US marks a significant milestone in executing their personalised nutrition strategy, expanding customer value. This strategy leverages both scientific product development and extensive distributor support, indicating a multi-channel approach to market penetration.
Many leading brands in this category are manufactured in partnership with Supplement Factory.